Tolterodine extended release improves patient-reported outcomes in overactive bladder: Results from the IMPACT trial

International Journal of Clinical Practice

Volumn 60, Issue 6, 2006, Pages 752-758

  Roberts, Richard ^a   Bavendam, T ^b   Glasser, D B ^b   Carlsson, M ^b   Eyland, N ^b   Elinoff, V ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b PFIZER INC   (United States)

^c Regional Clinical Research Inc   (United States)

Author keywords

AUA SI; Bothersome symptoms; OAB q; Overactive bladder; Patient reported outcomes; PPBC; Tolterodine; Urgency; Urgency urinary incontinence

Indexed keywords

TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; DRUG RELEASE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OVERACTIVE BLADDER; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SOCIAL INTERACTION; STATISTICAL SIGNIFICANCE; URINARY FREQUENCY; URINARY URGENCY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PHENYLPROPANOLAMINE; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 33744540100     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00987.x     Document Type: Article

References (25)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61: 37-49.
2. Emery M-P, Perrier L-L, Acquadro C. Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID): Frequently asked questions. Health Qual Life Outcomes 2005; 3: 12.
3. Studenski S, Hayes RP, Leibowitz RQ et al. Clinical Global Impression of Change in Physical Frailty: Development of a measure based on clinical judgment. J Am Geriatr Soc 2004; 52: 1560-6.
4. Abrams P, Kelleher C, Lerr L et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6: S580-90.
5. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004; 7: 455-63.
6. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: Results from a U.S. community-based survey. Urology 2001; 57: 1044-50.
7. Ricci JA, Baggish JS, Hunt TL et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther 2001; 23: 1245-59.
8. Papanicolaou S, Hunskaar S, Lose G et al. Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK. BJU Int 2005; 96: 831-8.
9. Elinoff V, Bavendam T, Glasser DB et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. Int J Clin Pract 2006; 60: 745-51.
10. Matza LS, Thompson CL, Krasnow J et al. Test-retest reliability of four questionnaires for patients with overactive bladder: The Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005; 24: 215-25.
11. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002; 11: 563-74.
12. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57; discussion 1564.
13. Coyne K, Matza L. Patient perception of bladder condition is a valid tool for evaluating the efficacy of overactive bladder therapy. Int Urogynecol J Pelvic Floor Dysfunct 2002; 13: 83.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch, 1976.
15. Scarpero HM, Fiske J, Xue X et al. American Urological Association Symptom Index for lower urinary tract symptoms in women: Correlation with degree of bother and impact on quality of life. Urology 2003; 61: 1118-22.
16. Coyne K, Matza LS. Validation of the perception of bladder condition measure in overactive bladder. Value Health 2002; 5: 277 [abstract].
17. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002; 24: 616-28.
18. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 2004; 18: 351-63.
19. Coyne K, Matza L, Thompson C et al. Determining the importance of change in the OAB-q. J Urol 2006; in press.
20. Khullar V, Hill S, Laval K-U et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. Urology 2004; 64: 269-75.
21. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-6.
22. Yalla SV, Sullivan MP, Lecamwasam HS et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol 1995; 153: 674-79; discussion 679-80.
23. Rodrigues P, Meller A, Campagnari JC et al. International Prostate Symptom Score-IPSS-AUA as discriminate scale in 400 male patients with lower urinary tract symptoms (LUTS). Int Braz J Urol 2004; 30: 135-41.
24. Michel MC, Oelke M, Goepel M et al. What determines patient satisfaction in the treatment of overactive bladder? Presented at International Continence Society; 28 August to 2 September 2005, Montreal, Canada.
25. Hahn GJ, Meeker WQ. Statistical Intervals: A Guide for Practitioners. New York: John Wiley & Sons, 1991.